Previous research suggests that, while adhesion molecules like ICAM-1 and MAdCAM-1 also contribute to the treatment of inflammatory bowel diseases, selectively blocking VCAM-1 appears to offer higher potential efficacy in managing these conditions. Here, VCAM1 is linked to inflammatory bowel disease.